comparemela.com

Latest Breaking News On - Chris corsico - Page 9 : comparemela.com

GSK s gepotidacin shows potential in urinary tract infections

GSK PLC on Saturday announced positive phase three data that showed potential for its gepotidacin antibiotic to be the first in a new class of oral antibiotics for uncomplicated urinary tract. | April 17, 2023

City ofUnited kingdomChris corsicoHeather rydingsAlliance news ltdUs food drug administrationAlliance newsDrug administrationAll rightsGsk plc stock exchangePress releaseRinary gsk gb00bn7swp63

Stevenage scientists create first antibiotic in 20 years to treat UTIs

The first new antibiotic in more than 20 years that is capable of treating debilitating bladder infections, and is set to be approved for use in the…

Chris corsicoFlorian martin erich wagenlehnerGunnels wood road

GSK s Antibiotic Drug to Treat Uncomplicated UTIs Meets Main Goals

GSK said on Saturday its oral antibiotic drug to treat uncomplicated urinary tract infections in female adults and adolescents met the main goals in late-stage trials.

United statesUnited kingdomChris corsicoShilpi majumdarRadhika anilkumarDrug administrationUnited states food

GSK s antibiotic drug to treat uncomplicated UTIs meets main goals

GSK plans to submit results of the trials to the FDA for review later in the second quarter.

United statesUnited kingdomChris corsicoDrug administrationUnited states foodGsks antibiotic drug to treat uncomplicated utis meets main goals

GSK : Gepotidacin s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years

Gepotidacin is a late-stage antibiotic in development in GSK s growing infectious diseases portfolio EAGLE-2 and EAGLE-3 phase III trials met primary endpoint of. | April 15, 2023

United statesChris corsicoFlorian martin erich wagenlehnerTerm health outcomes among adultScynexis incEuropean congressClinical microbiologyInfectious diseasesIndependent data monitoring committeePrincipal investigatorAntibacterial gepotidacin evaluatedAntimicrobial resistance benchmarkSpero therapeuticsHart scott rodino antitrust improvements actAnnual reportUrinary tract

vimarsana © 2020. All Rights Reserved.